Featured Videos

STOCKHOLM, SWEDEN (UroToday.com) - This abstract was presented by Dr. Idir Ouzaid from Glickman Urological and Kidney Institute, Cleveland. The objective of this presentation was to compare perioperative and short-term outcomes of patients undergoing extracorporeal robotic assisted laparoscopic radical cystectomy (ecRARC) and intracorporeal robotic assisted laparoscopic radical cystectomy (icRARC) in a propensity matched fashion. Outcomes on 125 patients who underwent RARC and urinary diversion (UD) were presented. Of these, 45 and 80 patients underwent icRARC and ECRARC, respectively. Propensity-score matching was performed in a 1:1 ratio using disease characteristics (TURBT pathology and neoadjuvant chemotherapy), baseline demographics (age, gender, BMI, Charlson comorbidity score, history of smoking, and history of abdominal surgeries), and type of ileal UD (conduit and neobladders). Matched patients were compared with respect to their operative time, estimated blood loss (EBL), length of stay (LOS), time to oral diet, and 90-days complications. Ninety-days readmission and secondary procedure rates were also compared between the two cohorts.

eauThe group reported that patients who received icRARC had significantly lower EBL compared to the ecRARC group (p = 0.005) and the rate of transfusion was lower (22% vs. 42%, p = 0.07). Operative time, LOS, time to oral intake, as well as complication rates were reported similarly between the two cohorts.

In summary, robotic assisted laparoscopic radical cystectomy is gaining in popularity as an alternative to the open approach. Authors demonstrated that icRARC has the potential benefit of decreased estimated blood loss over ecRARC without additional morbidity and surgery time. Reported results should be further validated by other centers and larger cohorts.

Presented by Idir Ouzaid at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland USA

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 2

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
November 23-25, 2018 / European Society for Medical Oncology Asia 2018 Congress
European Society for Medical Oncology Asia 2018 Congress
November 25-30, 2018 / RSNA 2018 Annual Meeting
RSNA 2018 Annual Meeting